TABLE 1.
Demographics of study population
| Transplant (n=22)a | Control (n=21)a | ||
|---|---|---|---|
| Age, yr | 43.6±11.1 | 45.0±12.6 | P>0.05 |
| Male | 7 | 6 | |
| Female | 15 | 15 | |
| African American | 56% | 50% | |
| Hispanic | 17% | 14% | |
| Other | 26% | 36% | |
| Creatinine, mg/dL | 1.12±0.14 | 0.85±0.18 | P<0.05 |
| GFR, mL/min/1.73 m2 | 57.7±7.5 | 82.7±12.0 | P<0.05 |
| Time from transplant, mo | 28±20 | N/A | |
| Type of graft, % | |||
| Cadaveric | 41% | ||
| Living related | 27% | ||
| Living unrelated | 32% | N/A | |
| Percent with 2nd transplant (%) | 27% | N/A | |
| Immunosuppression dose | |||
| Tacrolimus <3 mg/d | 36% | ||
| Tacrolimus 3–6 mg/d | 32% | ||
| Tacrolimus >6 mg/d | 33% | ||
| Tacrolimus trough, ng/mL | 6.8±2.4 | N/A | |
| Induction therapy | |||
| Basiliximab/daclizumab | 39% | ||
| Thymoglobulin | 61% | N/A | |
| Cause of kidney failure | |||
| Hypertension | 36% | ||
| Diabetes | 27% | ||
| FSGS | 14% | ||
| SLE | 4% | ||
| PCKD | 5% | ||
| Unknown | 14% | N/A | |
a
Values are given as mean±SD.
FSGS, focal segmental glomerulosclerosis; PCKD, polycystic kidney disease; SLE, systemic lupus erythematosus.